Claritas Collaborates with CMAX to Initiate P-I Study of R-107 for Pulmonary Arterial Hypertension

 Claritas Collaborates with CMAX to Initiate P-I Study of R-107 for Pulmonary Arterial Hypertension

Claritas Collaborates with CMAX to Initiate P-I Study of R-107 for Pulmonary Arterial Hypertension

Shots:

  • The P-I study will evaluate the PK and safety profile of R-107 vs PBO in patients with PAH. Earlier, Claritas licensed R-107 from Salzman Group and collaborated with it, under which get an exclusive WW right to develop R-107 for the treatment of PAH
  • CMAX will initiate a P-Ia study for R-107 (IM) and enroll 32 healthy middle-aged volunteers in 4 ascending dose cohorts. The study is expected to begin enrollment in Q3’21 with 2mos. duration
  • The P-Ia data will support the POC P-IIa study for the treatment of PAH patients undergoing cardiac catherization as part of their routine medical care. The study is expected to be initiated in H1’22

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Fresh 92.7

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post